Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

Core Evid · 2010 · PMC2899784 · PMID 20694072

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

approaching significanceP =0.056so close (0.05 < p ≤ 0.1)

However, all of the golimumab dose regimens showed numerically higher proportions of subjects achieving an ACR 20 response compared with placebo, with the 50 mg every four weeks arm approaching significance ( P =0.056).

also in 2,640 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.